MRNAModerna Inc.
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $0.38Beat
- vs −$1.10 expected on Nov 6
- Stock move on it
- +5.27%
- one session
- Price
- $231.38
- −6.96% today · $23.7B cap
Past and upcoming reports
1
| Nov 6, 2026 | Sep 30, 2026 | Time not given | −$1.10 | Beat$0.38 | +5.27% |
After the report
Nov 6, 2026 report
Moderna beat EPS estimates, while oncology expectations and valuation risk remain elevated
Moderna reported $0.38 EPS versus a consensus loss estimate of $1.25 on November 6, while shares rose 5.8% to $268.94 on November 9. The investment case still depends on cancer-pipeline follow-up data, with no quantified guidance update or post-earnings news provided.
Reported against expected
BeatReported EPS was $0.38 versus estimated EPS of -$1.25, a 130.29% beat on November 6, 2026.
Guidance
No quantified forward guidance or guidance change was provided in the payload. guidance tone is unknown.
How the stock reacted
Shares gained $14.75, or 5.8%, to $268.94 on November 9, with 12.3 million shares traded. the event-day and subsequent daily reactions were not separately provided.
What changed
EPS shifted from an expected $1.25 loss to reported earnings of $0.38, a $1.63 positive surprise.
What the price now assumes
The 5.8% rise and $268.94 price reflect support for oncology potential despite a $145.38 analyst target.
What it means for the business
Maintain a mixed bias. upgrade only if ASH follow-up cancer data confirms early responses.
The next one to three months, as we saw it then
Better case30%
Confirmed follow-up oncology data could support the pipeline value implied by the recent 19.56% monthly gain.
Base case45%
The EPS beat supports sentiment, but the 15-to-1 hold-to-buy analyst split and unavailable valuation metrics limit conviction.
Worse case25%
A failure to validate early oncology responses could compress the pipeline value supporting a stock up 996.17% over one year.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.